These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 35836102)

  • 21. Clinical Analysis of Polyethylene Glycol Interferon-α Treatment in 155 Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB) Patients.
    Luo X; Yu JX; Xie L; Ma WJ; Wang LH
    Ann Hepatol; 2017 November-December,; 16(6):888-892. PubMed ID: 29055925
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Quantitative serum HBsAg and HBeAg are strong predictors of sustained HBeAg seroconversion to pegylated interferon alfa-2b in HBeAg-positive patients.
    Ma H; Yang RF; Wei L
    J Gastroenterol Hepatol; 2010 Sep; 25(9):1498-506. PubMed ID: 20796146
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Efficacy of pegylated-interferon alpha-2a treatment in patients with HBeAg-positive chronic hepatitis B and partial viral response to nucleoside analogue therapy].
    Li MH; Hu LP; Zhang L; Lu Y; Shen G; Wu SL; Chang M; Mu CQ; Wu YZ; Yang M; Song SJ; Zhang SF; Hua WH; Xie Y; Cheng J; Xu DZ
    Zhonghua Gan Zang Bing Za Zhi; 2015 Nov; 23(11):826-31. PubMed ID: 26743242
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prospective, multicentre, randomised controlled trial comparing the seroclearance of HBsAg between combination therapy of peg-interferon alpha and tenofovir with tenofovir monotherapy in nucleos(t)ide analogue-experienced patients with HBV-related liver fibrosis: a study protocol.
    Zhu S; Wu L; Mei Y; Liu Z; Lin L; Yuan J; Li J; Li X; Peng L
    BMJ Open; 2021 Oct; 11(10):e049104. PubMed ID: 34697111
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sequential combination therapy with pegylated interferon leads to loss of hepatitis B surface antigen and hepatitis B e antigen (HBeAg) seroconversion in HBeAg-positive chronic hepatitis B patients receiving long-term entecavir treatment.
    Li GJ; Yu YQ; Chen SL; Fan P; Shao LY; Chen JZ; Li CS; Yi B; Chen WC; Xie SY; Mao XN; Zou HH; Zhang WH
    Antimicrob Agents Chemother; 2015 Jul; 59(7):4121-8. PubMed ID: 25941216
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [HBsAg loss with Pegylated-interferon alfa-2a in hepatitis B patients with partial response to nucleos(t)-ide analog: new switch study].
    Hu P; Shang J; Zhang WH; Gong GZ; Li YG; Chen XY; Jiang JN; Xie Q; Dou XG; Sun YT; Li YF; Liu YX; Liu GZ; Ma DW; Chi XL; Tang H; Li XO; Xie Y; Chen XP; Jiang JJ; Zha P; Hou JL; Gao ZL; Fan HM; Ding JG; Zhang DZ; Ren H
    Zhonghua Gan Zang Bing Za Zhi; 2018 Oct; 26(10):756-764. PubMed ID: 30481882
    [No Abstract]   [Full Text] [Related]  

  • 27. Role of a 48-week pegylated interferon therapy in hepatitis B e antigen positive HIV-co-infected patients on cART including tenofovir: EMVIPEG study.
    Miailhes P; Maynard-Muet M; Lebossé F; Carrat F; Bouix C; Lascoux-Combe C; Sogni P; Rey D; Barthe Y; Pol S; Cacoub P; Zoulim F; Piroth L
    J Hepatol; 2014 Oct; 61(4):761-9. PubMed ID: 24882048
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pilot study of tenofovir disoproxil fumarate and pegylated interferon-alpha 2a add-on therapy in Japanese patients with chronic hepatitis B.
    Matsumoto A; Nishiguchi S; Enomoto H; Tanaka Y; Shinkai N; Okuse C; Kang JH; Matsui T; Miyase S; Yatsuhashi H; Nagaoka S; Kanda T; Enomoto M; Yamada R; Hiramatsu N; Saito S; Takaguchi K; Ito K; Masaki T; Morihara D; Tsuge M; Chayama K; Ikeda F; Kagawa T; Kondo Y; Murata K; Tanaka E
    J Gastroenterol; 2020 Oct; 55(10):977-989. PubMed ID: 32666202
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of interferon alpha-2b versus pegylated interferon alpha-2a monotherapy in children with chronic hepatitis B: a real-life cohort study from Shanghai, China.
    Hu Y; Ye YZ; Ye LJ; Wang XH; Yu H
    World J Pediatr; 2019 Dec; 15(6):595-600. PubMed ID: 31487005
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combination and Intermittent Therapy Based on Pegylated Interferon Alfa-2a for Chronic Hepatitis B with Nucleoside (Nucleotide) Analog-Experienced Resulting in Hepatitis B Surface Antigen Clearance: A Case Report.
    Lin YJ; Sun FF; Zeng Z; Bi XY; Yang L; Li MH; Xie Y
    Viral Immunol; 2022; 35(1):71-75. PubMed ID: 34714178
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combination therapy with pegylated interferon alpha-2b and adefovir dipivoxil in HBeAg-positive chronic hepatitis B versus interferon alone: a prospective, randomized study.
    Liu YH; Wu T; Sun N; Wang GL; Yuan JZ; Dai YR; Zhou XH
    J Huazhong Univ Sci Technolog Med Sci; 2014 Aug; 34(4):542-547. PubMed ID: 25135724
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The efficacy and safety of pegylated interferon α-2b-based immunotherapy for inactive hepatitis B surface antigen carriers.
    Ning H; Li K; Peng Z; Jin H; Zhao H; Shang J
    Eur J Gastroenterol Hepatol; 2023 Oct; 35(10):1216-1223. PubMed ID: 37577817
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment with Peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype.
    Flink HJ; van Zonneveld M; Hansen BE; de Man RA; Schalm SW; Janssen HL;
    Am J Gastroenterol; 2006 Feb; 101(2):297-303. PubMed ID: 16454834
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Baseline HBsAg and HBcrAg titres allow peginterferon-based 'precision medicine' in HBeAg-negative chronic hepatitis B patients.
    Martinot-Peignoux M; Lapalus M; Maylin S; Boyer N; Castelnau C; Giuily N; Pouteau M; Moucari R; Asselah T; Marcellin P
    J Viral Hepat; 2016 Nov; 23(11):905-911. PubMed ID: 27375231
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial.
    Bourlière M; Rabiega P; Ganne-Carrie N; Serfaty L; Marcellin P; Barthe Y; Thabut D; Guyader D; Hezode C; Picon M; Causse X; Leroy V; Bronowicki JP; Carrieri P; Riachi G; Rosa I; Attali P; Molina JM; Bacq Y; Tran A; Grangé JD; Zoulim F; Fontaine H; Alric L; Bertucci I; Bouvier-Alias M; Carrat F;
    Lancet Gastroenterol Hepatol; 2017 Mar; 2(3):177-188. PubMed ID: 28404133
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HBsAg and HBeAg in the prediction of a clinical response to peginterferon α-2b therapy in Chinese HBeAg-positive patients.
    Yang S; Xing H; Wang Y; Hou J; Luo D; Xie Q; Ning Q; Ren H; Ding H; Sheng J; Wei L; Chen S; Fan X; Huang W; Pan C; Gao Z; Zhang J; Zhou B; Chen G; Wan M; Tang H; Wang G; Yang Y; Xu D; Dong P; Wang Q; Wang J; Bognar FA; Xu D; Cheng J
    Virol J; 2016 Oct; 13(1):180. PubMed ID: 27793166
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline.
    Sonneveld MJ; Rijckborst V; Boucher CA; Hansen BE; Janssen HL
    Hepatology; 2010 Oct; 52(4):1251-7. PubMed ID: 20830787
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of chronic hepatitis B naïve patients with a therapeutic vaccine containing HBs and HBc antigens (a randomized, open and treatment controlled phase III clinical trial).
    Al Mahtab M; Akbar SMF; Aguilar JC; Guillen G; Penton E; Tuero A; Yoshida O; Hiasa Y; Onji M
    PLoS One; 2018; 13(8):e0201236. PubMed ID: 30133478
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pegylated Interferon Alfa-2b Add-on Treatment in Hepatitis B Virus Envelope Antigen-Positive Chronic Hepatitis B Patients Treated with Nucleos(t)ide Analogue: A Randomized, Controlled Trial (PEGON).
    Chi H; Hansen BE; Guo S; Zhang NP; Qi X; Chen L; Guo Q; Arends P; Wang JY; Verhey E; de Knegt RJ; Xie Q; Janssen HLA
    J Infect Dis; 2017 Apr; 215(7):1085-1093. PubMed ID: 28329061
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of fibrosis regression of entecavir alone or combined with pegylated interferon alpha2a in patients with chronic hepatitis B.
    Chen S; Zhou J; Wu X; Meng T; Wang B; Liu H; Wang T; Zhao X; Kong Y; Wu S; Ou X; Jia J; Sun Y; You H
    Hepatol Int; 2021 Jun; 15(3):611-620. PubMed ID: 33677771
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.